Cargando…
Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States
OBJECTIVE: Microsatellite instability (MSI) due to defective DNA mismatch repair has emerged as an actionable biomarker in advanced endometrial cancer (aEC). Currently, there are no treatment patterns and outcomes data in non-MSI-high (non-MSI-H) or mismatch repair proficient (pMMR) aEC patients fol...
Autores principales: | Kelkar, Sneha S., Prabhu, Vimalanand S., Zhang, Jingchuan, Corman, Shelby, Macahilig, Cynthia, Rusibamayila, Nifasha, Odak, Shardul, Duska, Linda R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253581/ https://www.ncbi.nlm.nih.gov/pubmed/35800987 http://dx.doi.org/10.1016/j.gore.2022.101026 |
Ejemplares similares
-
Gene Expression Profile Reveals a Prognostic Signature of Non–MSI-H/pMMR Colorectal Cancer
por: Liu, Zaoqu, et al.
Publicado: (2022) -
Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients
por: Wu, Qing, et al.
Publicado: (2023) -
A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
por: Zhu, Jiangpeng, et al.
Publicado: (2023) -
Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
por: Gou, Miaomiao, et al.
Publicado: (2022) -
Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer
por: Ding, Yuwei, et al.
Publicado: (2023)